DNA icon

GJB2 Regulatory Element Deletion Testing (GJB6-D13S1830 and GJB6-D13S1854)

Summary and Pricing

Test Method

Targeted Deletion Testing via PCR
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
GJB2 81479 81479 $350
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
2997GJB281479 81479 $350 Order Options and Pricing

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Turnaround Time

4 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

EMAIL CONTACTS

Genetic Counselors

Geneticist

  • Ben Dorshorst, PhD

Clinical Features and Genetics

Clinical Features

Pathogenic variants in GJB2 are one of the most common causes of hereditary nonsyndromic hearing loss (NSHL), typically exhibiting autosomal recessive (AR) inheritance and characterized by congenital, mild to profound sensorineural hearing loss. This test is specific for two previously reported GJB2 regulatory element deletions that have been documented to be pathogenic for AR hearing loss.

Hearing loss (HL) or deafness is the most common sensory deficit in humans, affecting an estimated 5% of the world's population (Azaiez et al. 2018. PubMed ID: 30245029). Molecular genetic testing is possible for many types of hearing loss and plays a prominent role in diagnosis, genetic counseling, evaluating hearing loss stability and potential of undiagnosed related clinical features (Shearer et al. 2017. PubMed ID: 20301607).

Genetics

While the vast majority of GJB2 pathogenic variants for NSHL display AR inheritance, a small number of have been documented to cause autosomal dominant (AD) NSHL with early to late childhood onset, as well as several AD syndromic disorders with mild to severe skin features either with or without hearing loss (Smith et al. 2016. PubMed ID: 20301449).  

GJB2 variants causing AR NSHL span the variant effect spectrum including missense, premature termination, splicing, regulatory, insertion/deletion, and gross deletion variants. Only missense variants have been associated with AD NSHL or syndromic GJB2-related disorders (Smith and Jones. 2016. PubMed ID: 20301449; Del Castillo and Del Castillo. 2017. PubMed ID: 29311818).

The most common GJB2 pathogenic sequence variants for AR NSHL and respective allele frequencies are c.167del in Ashkenazi Jewish (1.6%), c.35del in European (0.97%), and c.235del in East Asian populations (0.64%) (Chan and Chang. 2014. PubMed ID: 23900770; Genome Aggregation Database).

A small number of large deletions upstream of but not containing the GJB2 gene have been documented to cause AR NSHL, spanning the GJB6 and CRYL1 genes. While originally attributed to digenic inheritance between GJB2 and GJB6, functional studies have shown that these deletions result in loss of expression of GJB2 on the same allele as the deletion. Therefore, these deletions contain an essential GJB2 cis-regulatory element (Rodriguez-Paris and Schrijver, 2009. PubMed ID: 19723508; Del Castillo and Del Castillo. 2017. PubMed ID: 29311818).). A 95 kb critical region for this GJB2 regulatory element has been established by comparing overlapping deletions in different patients (Tayoun et al. 2016. PubMed ID: 26444186), and contains the last 5 exons of CRYL1 as well as GJB6-CRYL1 intergenic sequence.

The most common GJB2 regulatory element deletions that have been reported are the 309 kb GJB6-D13S1830 and 232 kb GJB6-D13S1854 deletions, both spanning from GJB6 to CRYL1. In patients with NSHL and a single potentially pathogenic variant in GJB2, these two large deletions were detected in 0-42% and 0-25% of cases across different populations, respectively (del Castillo et al. 2003. PubMed ID: 14571368; del Castillo. 2005. PubMed ID: 15994881; Pandya et al. 2020. PubMed ID: 32067424). The GJB6-D13S1830 and GJB6-D13S1854 deletions account for 1-10% of variants in patients with GJB2-associated hearing loss of European ancestry, with the GJB6-D13S1830 deletion being more frequent (Bliznetz et al. 2017. PubMed ID: 28405014).

The GJB2 gene codes for the gap junction beta 2 protein, also known as connexin 26. Connexins form gap junctions that permit the transport of nutrients, ions, and signaling molecules between neighboring cells that are in contact with each other. Connexin 26 transports potassium ions and some small molecules. GJB2 gene variants alter gap junctions, which may disturb the level of potassium ions in the inner ear. Levels of potassium ions that are too high may affect the function and survival of cells that are needed for hearing. Connexin 26 also plays a role in the growth, maturation, and stability of the outermost layer of skin, the epidermis (Jagger and Forge. 2015. PubMed ID: 25381570; Smith and Jones. 2016. PubMed ID: 20301449).

Clinical Sensitivity - Targeted Deletion

The clinical sensitivity of this test is difficult to estimate given the genetic heterogeneity of hearing loss. This test will detect the two most common large deletions of GJB2 regulatory elements (GJB6-D13S1830 and GJB6-D13S1854), but will not detect deletions in this region with different breakpoints.

Testing Strategy

A PCR based deletion test is used to detect the two most common large deletions of GJB2 regulatory elements (GJB6-D13S1830 and GJB6-D13S1854).

Indications for Test

Patients with hearing loss and a single causative GJB2 variant should consider this test to identify a second GJB2 variant related to autosomal recessive hearing loss.

Gene

Official Gene Symbol OMIM ID
GJB2 121011
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Citations

  • Azaiez et al. 2018. PubMed ID: 30245029
  • Bliznetz et al. 2017. PubMed ID: 28405014
  • Chan and Chang. 2014. PubMed ID: 23900770
  • del Castillo and del Castillo. 2017. PubMed ID: 29311818
  • del Castillo et al. 2003. PubMed ID: 14571368
  • del Castillo. 2005. PubMed ID: 15994881
  • Genome Aggregation Database (gnomAD).
  • Jagger and Forge. 2015. PubMed ID: 25381570
  • Pandya et al. 2020. PubMed ID: 32067424
  • Rodriguez-Paris and Schrijver. 2009. PubMed ID: 19723508
  • Shearer et al. 2017. PubMed ID: 20301607
  • Smith and Jones. 2016. PubMed ID: 20301449
  • Tayoun et al. 2016. PubMed ID: 26444186

Ordering/Specimens

Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page


Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×

ORDER OPTIONS

An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)


1) Select Test Type


2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
×
Copy Text to Clipboard
×